Close
Smartlab Europe
Achema middle east

Industry Reports

Infinity Reports First Quarter 2012 Financial Results

Infinity Pharmaceuticals, Inc.today reported its financial results for the first quarter of 2012. The company maintained its strong financial condition while continuing to advance its clinical programs during the quarter toward the key development milestones expected in the...

Pfizer reports first-quarter 2012 results

Pfizer Inc. today reported financial results for first-quarter 2012. First-quarter 2012 revenues were $15.4 billion, a decrease of 7% compared with $16.5 billion in the year-ago quarter, which reflects an operational decline of $1.0 billion, or 6%, and...

Revenue of first quarter 2012

ADOCIA, a biotechnology company specialized in the development of best-in-class medicines with already-approved therapeutic proteins, announces today revenues of EUR 1.2 million for the first quarter of 2012 compared to EUR 0.6 million for the same quarter last year.  ...

Pfizer reports fourth-quarter and full-year 2011 results

Pfizer Inc. reported financial results for fourth-quarter and full-year 2011. Fourth-quarter 2011 revenues were $16.7 billion, a decrease of 4% compared with $17.4 billion in the year-ago quarter, which reflects an operational decline of $765 million, or 5%, and the favorable...

NxStage® to Report Fourth Quarter and Full Year 2011 Financial Results

NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2011 on Wednesday, February 29, 2012  before the...

Cubist Pharmaceuticals Reports 2011 Fourth Quarter and Full Year Financial Results

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the fourth quarter and year ended December 31, 2011. The Company will host a conference call and webcast today at 5:00 p.m. ET to discuss these results and other...

Stable consolidated revenues, costs and losses for Hybrigenics

Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases and specialised in protein interactions, today presents its consolidated accounts for the first half...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »